239
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents

, , , , , , , , , , , , , , , & show all
Pages 3245-3248 | Received 05 May 2022, Accepted 02 Aug 2022, Published online: 15 Sep 2022
 

Disclosure statement

P.V. has a consulting or advisory role with Blueprint Medicines, Incyte, Abbvie, Jazz Pharmaeuticals, CTI BioPharma Corp, Novarts, Amgen, Pfizer. S.B. has a consulting/advisory role with Syneos Health Independent Data Monitoring Committee. S.W. has a consulting/advisory role with Blueprint Medicines and CTI BioPharma Corp.

Additional information

Funding

No financial support was utilized in the preparation of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.